China-based biopharmaceutical firm IMPACT Therapeutics has completed its Series D+ funding round at 400 million yuan ($55.2 million) to advance its pipeline of anti-cancer therapeutics.
Continue Reading: Unlock Free Insights!
Stay updated with 3 free articles every month
Access our exclusive newsletters delivered to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
